All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @anabolicarcc on Instagram ยท 74s|Watch on Instagram
Full video transcriptClick to expand

Auto-generated transcript of @anabolicarcc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Hello everyone and welcome to confession number 8. Hello coach, I mixed GHR B6 and CJC 1,
  2. 0:072, 9, 5 in same while. Didn't my other ratio properly, in fact, bloated. Face popped. Hand
  3. 0:14went now. Later found out I overdosed on GHR B. Wrong dilution.
  4. 0:21That's the classic peptide panic. They go with the same name of both the child and
  5. 0:24GHR B6 or CJC comic scale. It is a very simple, what can you say mixture, what's the
  6. 0:29number of
  7. 0:33the child?
  8. 0:36MyWhenwe talk of this, I have been saying magnesium in every country and it is not enough
  9. 0:43I have been saying that it is too fast, but now I am not sure if I am...
  10. 0:45I have been saying of X-ray, we have been saying...
  11. 0:48I am saying that it is too fast, and I am saying it is too fast, and so it just has been
  12. 0:53it is too fast, but let's say this is a very bad where I am saying very bad, but now the
  13. 0:58thing we do is, we have been saying patent out, patent out, patent out, patent out, patent
  14. 1:03peptides are science not the guesswork. Don't assume safe means simple. So DM your anonymous
  15. 1:11confessions at anabolic arc ARW.

@anabolicarcc's peptide safety warnings, fact-checked

๐•๐š๐ซ๐ฎ๐ง ๐ƒ๐ก๐ข๐ซ โ„ข

Instagram creator

15.2K viewsView on Instagram โ†’

Quick answer

The case described involves GHRP-6 and CJC-1295 co-administration with a reconstitution error resulting in supraphysiologic GH stimulation, producing water retention and peripheral paresthesia consistent with GH excess. These are recognized adverse effects documented in both therapeutic GH literature and ghrelin receptor agonist pharmacology studies. Neither peptide is FDA-approved for the indications described, and both carry meaningful risks when used without clinical supervision and precise dosing protocols.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 5 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @anabolicarcc's peptide safety warnings, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@anabolicarcc's peptide safety warnings, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this cjc-1295 video claims cluster

Best for searchers checking whether growth-hormone peptide claims fit evidence, access, and safety realities.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@anabolicarcc's peptide safety warnings, fact-checked" from ๐•๐š๐ซ๐ฎ๐ง ๐ƒ๐ก๐ข๐ซ โ„ข. We read the clip as a Peptide social video fact-checks claim about CJC-1295, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The case described involves GHRP-6 and CJC-1295 co-administration with a reconstitution error resulting in supraphysiologic GH stimulation, producing water retention and peripheral paresthesia consistent with GH excess.

The reason this review is not generic is the source wording and the canonical claim label "peptides cycle confessions episode 9 the peptide panic he thoug." In this clip, the useful excerpt is: "Hello everyone and welcome to confession number 8." That wording changes the review because it points to CJC-1295 evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. CJC-1295 decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Facial water retention and hand numbness from GH excess are well-documented: Giustina et al.
People who land here are usually comparing the CJC-1295 claim with CycleConfessions, ThePeptidePanic, and AnabolicArcc.
The strongest next step is to compare the claim with FormBlends' CJC-1295 guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The case described involves GHRP-6 and CJC-1295 co-administration with a reconstitution error resulting in supraphysiologic GH stimulation, producing water retention and peripheral paresthesia consistent with GH excess.

FormBlends verdict

CJC-1295 evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The case described involves GHRP-6 and CJC-1295 co-administration with a reconstitution error resulting in supraphysiologic GH stimulation, producing water retention and peripheral paresthesia consistent with GH excess. These are recognized adverse effects documented in both therapeutic GH literature and ghrelin receptor agonist pharmacology studies. Neither peptide is FDA-approved for the indications described, and both carry meaningful risks when used without clinical supervision and precise dosing protocols.
  • GHRP-6 at supraphysiologic doses stimulates cortisol and prolactin in addition to GH, increasing adverse effect risk beyond simple GH excess (Arvat et al., 1997, European Journal of Endocrinology).
  • Facial water retention and hand numbness from GH excess are well-documented: Giustina et al. (2008) reviewed these as characteristic signs in both acromegaly and therapeutic GH overdose scenarios.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • GHRP-6 at supraphysiologic doses stimulates cortisol and prolactin in addition to GH, increasing adverse effect risk beyond simple GH excess (Arvat et al., 1997, European Journal of Endocrinology).
  • Facial water retention and hand numbness from GH excess are well-documented: Giustina et al. (2008) reviewed these as characteristic signs in both acromegaly and therapeutic GH overdose scenarios.
  • A 2021 Drug Testing and Analysis study by Rasmussen et al. found significant labeling inaccuracies in black-market peptide products, including wrong concentrations and microbial contamination.
  • Reconstituting a 2 mg peptide vial in 1 mL versus 2 mL of bacteriostatic water produces a twofold difference in dose per unit drawn. This is the math behind most peptide overdose cases.
  • Neither GHRP-6 nor CJC-1295 is FDA-approved for human use. Both are classified as research chemicals, meaning no regulatory quality control applies to commercial supplies.
  • Combining a GHRH analogue (CJC-1295) with a ghrelin mimetic (GHRP-6) produces additive GH release confirmed in research (Ionescu and Frohman, 2006, Endocrinology), which also means additive risk when dosed incorrectly.
  • Peripheral paresthesia from peptide-driven GH excess typically resolves with dose reduction but warrants medical evaluation if persistent, as it can indicate fluid-related nerve compression.

Our take ยท Written by FormBlends editorial team ยท Reviewed by FormBlends Medical Team ยท This is not a transcript. It is our independent review of the video above.

What did @anabolicarcc actually say?

The transcript is partially garbled, likely from auto-captioning, but the core narrative is clear enough: a user mixed GHRP-6 and CJC-1295 in the same syringe, got the dilution wrong, and ended up with facial bloating and hand numbness. The creator attributes this to "wrong dilution" and overdosing on GHRP-6. The closing line lands reasonably well: "peptides are science not guesswork. Don't assume safe means simple." That framing is the most defensible thing in this video.

The creator also name-checks magnesium supplementation as something they recommend across markets, though this comes through in a fragmented way and lacks any clinical context in the transcript. It is not clear whether this is a recommendation for managing side effects or something else entirely.

Does the science back this up?

On the core claim, yes, mostly. GHRP-6 is a ghrelin mimetic that stimulates growth hormone release. CJC-1295 is a GHRH analogue. Combining them is common in fitness communities because they act on different receptors and produce additive GH release. That part is real. A 2006 study by Ionescu and Frohman in Endocrinology confirmed that GHRH analogues and ghrelin receptor agonists have synergistic GH-releasing effects.

The side effects described, including water retention causing facial puffiness and peripheral paresthesia (hand numbness), are consistent with excess GH stimulation. Elevated IGF-1 from supraphysiologic GH pulses is associated with fluid retention and carpal tunnel-like symptoms. This is documented in acromegaly literature and in growth hormone therapy adverse event data reviewed by Giustina et al. (2008, Journal of Clinical Endocrinology and Metabolism). Overdosing GHRP-6 specifically would amplify these effects because it also stimulates cortisol and prolactin at higher doses, per Arvat et al. (1997, European Journal of Endocrinology).

What did they get wrong (or right)?

They got the mechanism directionally right. High-dose GHRP-6 causes exactly the constellation of symptoms described. Credit where it is due.

What they got wrong, or at least significantly underexplained, is the reconstitution point. The creator says the person "didn't mix their ratio properly" but never explains what that actually means. Bacteriostatic water concentration matters enormously with peptides. A common error is using too little diluent, which concentrates the dose, or drawing an incorrect volume. A 2 mg vial reconstituted in 1 mL versus 2 mL produces a dramatically different dose per unit volume. This is not esoteric knowledge, it is basic pharmaceutical calculation, and glossing over it as just a "wrong dilution" without explaining the math leaves viewers no better equipped to avoid the same error.

The magnesium tangent is unsubstantiated in context. There is no established evidence that magnesium supplementation mitigates GHRP-6 or CJC-1295 side effects specifically. Presenting it as a cross-market recommendation without sourcing is not great practice.

What should you actually know?

GHRP-6 and CJC-1295 are not approved by the FDA for human use outside clinical trials. They are sold as research chemicals. The sources matter enormously because peptide purity varies widely in unregulated markets. A 2021 analysis by Rasmussen et al. in Drug Testing and Analysis found significant labeling inaccuracies in black-market peptide products, including incorrect concentrations and microbial contamination.

Reconstitution errors are genuinely the most common harm vector with injectable peptides. The math is not complicated but it requires attention:

  • Always use bacteriostatic water, not sterile water, for multi-use vials.
  • Calculate concentration per unit volume before drawing any dose.
  • Do not mix multiple peptides in a single syringe without confirming chemical compatibility and pH stability.

The hand numbness described in this video is a known side effect of excess GH stimulation. It mirrors the carpal tunnel symptoms seen in patients on therapeutic growth hormone. It typically resolves when the dose is reduced or discontinued. If it does not resolve, that is a reason to seek medical evaluation, not to adjust the stack independently.

"Don't assume safe means simple" is the one line worth keeping from this video. Peptides carry real pharmacological effects and real risks. That framing is accurate even if the surrounding content is incomplete.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

๐•๐š๐ซ๐ฎ๐ง ๐ƒ๐ก๐ข๐ซ โ„ข ยท Instagram creator

15.2K views on this video

๐Ÿ’‰ Cycle Confessions โ€“ Episode 9: The Peptide Panic He thought peptides were safer than steroidsโ€ฆ until his hands went numb. Wrong ratios. Wrong reconstitution. Wrong source. Peptides can be game-cha

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about ghrp-6 at supraphysiologic doses stimulates cortisol?

GHRP-6 at supraphysiologic doses stimulates cortisol and prolactin in addition to GH, increasing adverse effect risk beyond simple GH excess (Arvat et al., 1997, European Journal of Endocrinology).

What does the video say about facial water retention?

Facial water retention and hand numbness from GH excess are well-documented: Giustina et al. (2008) reviewed these as characteristic signs in both acromegaly and therapeutic GH overdose scenarios.

What does the video say about a 2021 drug testing?

A 2021 Drug Testing and Analysis study by Rasmussen et al. found significant labeling inaccuracies in black-market peptide products, including wrong concentrations and microbial contamination.

What does the video say about reconstituting a 2 mg peptide vial in 1 ml versus?

Reconstituting a 2 mg peptide vial in 1 mL versus 2 mL of bacteriostatic water produces a twofold difference in dose per unit drawn. This is the math behind most peptide overdose cases.

What does the video say about neither ghrp-6 nor cjc-1295?

Neither GHRP-6 nor CJC-1295 is FDA-approved for human use. Both are classified as research chemicals, meaning no regulatory quality control applies to commercial supplies.

What does the video say about combining a ghrh analogue (cjc-1295) with a ghrelin mimetic (ghrp-6)?

Combining a GHRH analogue (CJC-1295) with a ghrelin mimetic (GHRP-6) produces additive GH release confirmed in research (Ionescu and Frohman, 2006, Endocrinology), which also means additive risk when dosed incorrectly.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ๐•๐š๐ซ๐ฎ๐ง ๐ƒ๐ก๐ข๐ซ โ„ข, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.